In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Exits RNAi, Raising Questions For Stalwarts

Executive Summary

In mid-November, in a move that seemingly came from the top, Roche opted to cease all activity in RNA interference technology, preferring to invest in other areas like next-generation antibodies and peptide therapeutics. These days RNAi company Alnylam might have some difficult questions to answer about its business development strategy - only nobody's really asking. That's because even as Roche weighs its options around divestiture of its RNAi license, technology and research sites, the future of Alnylam - and the field of RNAi more generally - is now tied solely to establishing clinical proof-of-concept for siRNA drugs, and eventually getting those drugs to market.
Advertisement

Related Content

Financings Of The Fortnight: Cutting-Edge Biomedical Technology Drawing Big Investments
MicroRNA Momentum Builds, But Will Big Pharma Embrace It?
The Alnylam Turnaround: What Changed Investors’ Minds?
Silence Therapeutics Raising $8.8M To Send RNAi Drug To Phase IIa
Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel